Prohibiting certain insurers, nonprofit health service plans, and health maintenance organizations from imposing a step therapy or fail-first protocol for certain prescription drugs used to treat a symptom of or side effect from the treatment of stage four metastatic cancer that the treating provider determines will negatively impact the insured or enrollee's health if left untreated and use of the prescription drug is consistent with best practices for treatment of the condition.